Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Integra Lifesciences Holdings (IART) Intangibles (2016 - 2025)

Integra Lifesciences Holdings' Intangibles history spans 17 years, with the latest figure at $1.2 billion for Q2 2025.

  • For Q2 2025, Intangibles fell 2.61% year-over-year to $1.2 billion; the TTM value through Jun 2025 reached $1.2 billion, down 2.61%, while the annual FY2024 figure was $1.2 billion, 13.09% up from the prior year.
  • Intangibles for Q2 2025 was $1.2 billion at Integra Lifesciences Holdings, down from $1.2 billion in the prior quarter.
  • Across five years, Intangibles topped out at $1.2 billion in Q2 2024 and bottomed at $1.0 billion in Q1 2024.
  • The 5-year median for Intangibles is $1.1 billion (2021), against an average of $1.1 billion.
  • The largest annual shift saw Intangibles increased 15.78% in 2021 before it dropped 5.22% in 2023.
  • A 5-year view of Intangibles shows it stood at $1.1 billion in 2021, then dropped by 1.66% to $1.1 billion in 2022, then decreased by 5.22% to $1.1 billion in 2023, then grew by 13.09% to $1.2 billion in 2024, then fell by 1.62% to $1.2 billion in 2025.
  • Per Business Quant, the three most recent readings for IART's Intangibles are $1.2 billion (Q2 2025), $1.2 billion (Q4 2024), and $1.2 billion (Q3 2024).